Overview
U.S. behavioral healthcare provider's Q1 revenue rose 7.6%, a slight beat versus analyst estimates
Adjusted EBITDA for Q1 rose and beat analyst expectations
Company raised full-year 2026 adjusted EBITDA and adjusted EPS guidance
Outlook
Acadia sees Q2 2026 revenue at $835 mln to $850 mln
Company raises 2026 adjusted EBITDA guidance to $580 mln-$615 mln
Acadia expects 2026 adjusted EPS of $1.35 to $1.60, up from prior $1.30-$1.55
Result Drivers
VOLUME GROWTH - Higher patient volumes in Acute and Residential Treatment Centers contributed to revenue and Adjusted EBITDA growth
REVENUE PER PATIENT DAY - Increase in revenue per patient day, partly due to supplemental payments from Tennessee and Ohio, supported same-facility revenue growth
EXPANDED CAPACITY - Additional licensed beds from new and existing facilities drove higher acute inpatient volumes
Company press release: ID:nBw8c2t3za
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Slight Beat*
$828.80 mln
$822.92 mln (12 Analysts)
Q1 Net Income
$4.46 mln
Q1 Adjusted EBITDA
Beat
$144.20 mln
$131.40 mln (13 Analysts)
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Acadia Healthcare Company Inc is $24.75, about 10.3% below its April 28 closing price of $27.58
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 7 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)